Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Moutabarrik A et al. | FK506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells. | 1992 | Transpl. Int. | pmid:14621744 |
Stangl MJ et al. | The use of FK506 and RS61443 for reversal of small-bowel rejection. | 1992 | Transpl. Int. | pmid:14621800 |
Wijnen RM et al. | Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. | 1992 | Transpl. Int. | pmid:14621844 |
Jiang H et al. | Control of humoral and cellular immunity-mediated accelerated heart allograft rejection in sensitized rats by low dose FK 506 and splenectomy. | 1992 | Transpl. Int. | pmid:14621859 |
Kobayashi N et al. | Abdominal organ cluster transplantation in pigs and FK506. | 1992 | Transpl. Int. | pmid:14621861 |
Galat A et al. | A rapamycin-selective 25-kDa immunophilin. | 1992 | Biochemistry | pmid:1371698 |
Metcalfe S et al. | FK506 and rapamycin: differential sensitivity of human, baboon, cynomolgus monkey, dog and pig lymphocytes. | 1992 | Transpl. Int. | pmid:14621863 |
Hanawa H et al. | An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. | 1992 | Clin. Immunol. Immunopathol. | pmid:1371730 |
Japanese study of kidney transplantation: 1. Results of early phase II study. | 1992 | Transpl. Int. | pmid:14621866 | |
Hiraoka Y et al. | The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis. | 1992 | J. Pharmacol. Exp. Ther. | pmid:1372051 |
Chen TS et al. | Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. | 1992 | J. Antibiot. | pmid:1372307 |
Morisaki M and Arai T | Identity of immunosuppressant FR-900520 with ascomycin. | 1992 | J. Antibiot. | pmid:1372308 |
Doi R et al. | Effects of FK506 on exocrine pancreas in rats. | 1992 | Pancreas | pmid:1372739 |
Furukawa H et al. | The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. | 1992 | Transplantation | pmid:1373531 |
Sakr M et al. | Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients. | 1992 | Transplantation | pmid:1373535 |
Kawaguchi S | [Effects of FK506 on aminonucleoside-induced nephrotic rats]. | 1992 | Nihon Jinzo Gakkai Shi | pmid:1375300 |
Sigal NH and Dumont FJ | Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. | 1992 | Annu. Rev. Immunol. | pmid:1375473 |
Chen TS et al. | Microbial transformation of immunosuppressive compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 900520 by an unidentified Actinomycete ATCC 53828 [corrected]. | 1992 | J. Antibiot. | pmid:1375593 |
Meingassner JG and Stütz A | Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? | 1992 | J. Invest. Dermatol. | pmid:1375617 |
Schneck FX et al. | Pediatric renal transplantation under FK-506 immunosuppression. | 1992 | J. Urol. | pmid:1375663 |
Ohtsuka S et al. | The effect of short-term FK 506 therapy on pancreas transplantation using the cuff technique in rats. | 1992 | Transplant. Proc. | pmid:1376532 |
Demetris AJ et al. | Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. | 1992 | Lancet | pmid:1376851 |
Ichihashi T et al. | Haemolytic uraemic syndrome during FK506 therapy. | 1992 | Lancet | pmid:1376852 |
O'Keefe SJ et al. | FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. | 1992 | Nature | pmid:1377361 |
Clipstone NA and Crabtree GR | Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. | 1992 | Nature | pmid:1377362 |
Hasegawa S et al. | Combination use of suboptimal dose of FK 506 and cyclosporine in canine lung transplantation. | 1992 | J. Thorac. Cardiovasc. Surg. | pmid:1279319 |
DiLella AG et al. | Chromosomal band assignments of the genes encoding human FKBP12 and FKBP13. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1281998 |
Sawada M et al. | Down regulation of CD4 expression in cultured microglia by immunosuppressants and lipopolysaccharide. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1282000 |
Minoda M et al. | Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. | 1992 | Microbiol. Immunol. | pmid:1282197 |
Min DI et al. | Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. | 1992 | Am J Hosp Pharm | pmid:1282779 |
Mochizuki M | [Immunotherapy in ocular diseases]. | 1992 | Nippon Ganka Gakkai Zasshi | pmid:1283052 |
Olejniczak ET et al. | A 4D HCCH-TOCSY experiment for assigning the side chain 1H and 13C resonances of proteins. | 1992 | J. Biomol. NMR | pmid:1283353 |
Kobayashi N et al. | Abdominal organ cluster transplantation in pigs receiving FK 506. | 1992 | Transplant. Proc. | pmid:1379754 |
Yoshimura R et al. | A comparative study of cyclosporine vs FK 506: role of kidney microsomal cytochrome P-450. | 1992 | Transplant. Proc. | pmid:1379755 |
Yamada K et al. | FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. | 1992 | Transplant. Proc. | pmid:1379756 |
Fukuse T et al. | Optimal dose of FK 506 in canine lung allotransplantation. | 1992 | Transplant. Proc. | pmid:1379757 |
Wada H et al. | Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. | 1992 | Transplant. Proc. | pmid:1379758 |
Cai X et al. | Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin. | 1992 | Transplant. Proc. | pmid:1379759 |
Taki J et al. | DNA analysis of peripheral blood mononuclear cells for early detection of hepatic graft rejection. | 1992 | Transplant. Proc. | pmid:1379760 |
Norris AA et al. | Protective effects of cyclophosphamide, cyclosporin A and FK506 against antigen-induced lung eosinophilia in guinea-pigs. | 1992 | Clin. Exp. Immunol. | pmid:1381297 |
Karpas A et al. | Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. | 1992 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1381509 |
Yatscoff RW and Shaw LM | Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. | 1992 | Ther Drug Monit | pmid:1381530 |
Arceci RJ et al. | Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. | 1992 | Blood | pmid:1381629 |
Pahl A and Keller U | FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. | 1992 | J. Bacteriol. | pmid:1381710 |
Takahashi N | [Cyclophilin and FK506-binding protein]. | 1992 | Seikagaku | pmid:1381737 |
Lee TK et al. | Mucosal glutamine utilization after small-bowel transplantation: an electrophysiologic study. | 1992 | J. Surg. Res. | pmid:1382152 |
Mochizuki M et al. | Preclinical and clinical study of FK506 in uveitis. | 1992 | Curr. Eye Res. | pmid:1385045 |
Chung J et al. | Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. | 1992 | Cell | pmid:1377606 |
Xu RX et al. | Stereospecific assignments and chi 1 rotamers for FKBP when bound to ascomycin from 3JH alpha,H beta and 3HN,H beta coupling constants. | 1992 | FEBS Lett. | pmid:1377648 |
Petros AM et al. | NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. | 1992 | J. Med. Chem. | pmid:1377749 |